Auto-injectors are devices that deliver a fixed dose of the drug to patients, hence these pen-like devices are becoming standard in the treatment of various conditions like multiple sclerosis, anaphylaxis, rheumatoid arthritis, etc. these devices are mostly used to reduce needle phobia and avoid injury due to the needle. Enhancing the ease of use, auto-injector manufacturers are focusing on using user-centric design. Moreover the high demand in biologics development, auto-injectors present opportunities for investors.
Study suggests need for education and awareness when using auto-injectors
According to a recent study, there is a need for more education and awareness, when it comes to using auto-injectors. With increasing allergies among children, most of the time people are unable to recognize the symptoms and are not able to use auto-injectors due to the lack of understanding. And within some time these allergies can turn into a severe condition. While using epinephrine can help in reversing the symptoms. Therefore, there is a need to educate people on how to use auto-injectors in such emergency situations.
According to the report by Future Market Insights (FMI), the global auto-injectors market is expected to register 15.1% CAGR during 2016-2026. It is also projected to reach close to $7,000 million value by 2026 end. The manufacturers are also focusing on user-centric design to overcome the challenge related to the self-administration of injections. On basis of indication, anaphylaxis is estimated to increase to 15% CAGR between 2016 and 2026, exceeding $6,000 million by 2026.
Auto-injectors are also reducing the dependency on healthcare providers. They are also reducing the time consumed at care units, providing reliable and in-expensive home medication. Moreover, auto-injectors are also developing generic versions to reduce the cost and provide better service at an affordable cost.
Enhanced features in auto-injectors to increase patient acceptance
Auto-injectors manufacturers are enhancing the features in their products to make it more convenient for patients and increase the use of such self-injection devices. Manufacturers are also creating awareness among patients with the technology and offering features such as safety, dose accuracy, easy-to-use, etc.
Manufacturers are also focusing on the feedback systems to develop auto-injectors by keeping in mind the requirements of the end-user. New medical devices are being made with the focus on features and certain specifications. Other key inputs considered while designing auto-injectors are injection depth, information related to primary container, viscosity range and others.
According to the survey in Germany, Betaconnect auto-injector, an electronic auto-injector by Bayer is the most preferred among patients for multiple sclerosis treatments.
Auto-injector devices are also being developed with reminder functions, as most of the time, people forget to take the self-administered drug. These auto-injectors are also being developed with the feature, providing an ability to adjust speed and depth of the injection.
A real-world study was evaluated patient satisfaction while administrating IFN β-1b using a new auto-injector known as ExtaviPro™30G. The study found that self-administrating with this new auto-injector improved overall patient satisfaction, also associated with convenience, side-effects and effectiveness in multiple sclerosis patients.
Request a Sample Report with Table of Contents: https://www.futuremarketinsights.com/reports/sample/rep-gb-1642